Rybelsus vs. Orlistat
Rybelsus and Orlistat take distinct approaches to weight management. Rybelsus, a GLP-1 receptor agonist, reduces appetite and improves glucose control, offering moderate weight loss. Orlistat, a lipase inhibitor, blocks fat absorption, resulting in modest weight loss without glucose benefits. Rybelsus causes nausea, while Orlistat is linked to gastrointestinal side effects like oily stools. Rybelsus costs $875/month, significantly more than Orlistat’s $100/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Blocks the breakdown and absorption of dietary fat in the intestines. Unabsorbed fat is excreted in the stool, reducing calorie intake and promoting weight loss.
Common Side Effects
Oily or fatty stools, frequent bowel movements, flatulence with discharge, and abdominal discomfort.
Serious Potential Side Effects
Rare liver damage and malabsorption of fat-soluble vitamins (A, D, E, K), kidney problems, and severe allergic reactions